Donal McLornan

Featured in: Favicon

nature.com Favicon

science.org Favicon

thelancet.com Favicon

futuremedicine.com Favicon

medicinejournal.co.uk Favicon

onlinelibrary.wiley.com

Articles

Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison | Bone Marrow Transplantation

Feb 20, 2024 | nature.com | Dietrich Wilhelm Beelen |Friedrich Stölzel |Fabio Ciceri |Wolfgang Andreas Bethge |Peter Dreger |Donal McLornan | +2 more

AbstractA randomized study (acronym: MC-FludT.14/L Trial II) demonstrated that fludarabine plus treosulfan (30 g/m²) was an effective and well tolerated conditioning regimen for allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT - Bone Marrow Transplantation

May 9, 2023 | nature.com | Meral Beksac |Patrice Chevallier |John A Snowden |Monika Engelhardt |Donal McLornan |Patrick J. Hayden | +1 more

AbstractEarly relapse (ER) following Autologous Hematopoietic Cell Transplantation (AHCT) confers a poor prognosis. We therefore developed a novel scoring system to predict ER. A total of 14,367 AHCT-1 patients were transplanted between 2014 and 2019, and were conditioned with Melphalan 200 mg/m2 (Mel200) (n = 7228; 2014–2017) (training cohort); Mel200 (n = 5616; 2018–2019) or Mel140 (n = 1523; 2018–2019) (validation cohorts).

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →